Epizyme (EPZM) Trading Up 19.2%

Epizyme Inc (NASDAQ:EPZM)’s share price was up 19.2% during mid-day trading on Thursday . The stock traded as high as $15.00 and last traded at $14.90. Approximately 784,200 shares were traded during mid-day trading, an increase of 45% from the average daily volume of 541,343 shares. The stock had previously closed at $12.50.

Several equities analysts have issued reports on EPZM shares. Morgan Stanley started coverage on shares of Epizyme in a research report on Wednesday. They issued an “overweight” rating and a $20.00 price target for the company. BidaskClub upgraded shares of Epizyme from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 5th. Royal Bank of Canada reiterated a “buy” rating and set a $20.00 price objective on shares of Epizyme in a research report on Friday, September 15th. Cann reiterated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Tuesday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Epizyme in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $22.40.

The company has a market cap of $1,080.00, a P/E ratio of -6.56 and a beta of 2.00.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. sell-side analysts forecast that Epizyme Inc will post -2.23 earnings per share for the current fiscal year.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $16.44, for a total transaction of $246,600.00. Following the transaction, the insider now directly owns 23,123 shares of the company’s stock, valued at $380,142.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 25.20% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in EPZM. Rhumbline Advisers lifted its stake in shares of Epizyme by 2.6% in the second quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock valued at $757,000 after buying an additional 1,257 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Epizyme in the second quarter valued at $408,000. SG Americas Securities LLC lifted its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares in the last quarter. Federated Investors Inc. PA lifted its position in shares of Epizyme by 477.6% during the second quarter. Federated Investors Inc. PA now owns 89,505 shares of the biopharmaceutical company’s stock valued at $1,352,000 after purchasing an additional 74,009 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Epizyme by 1.5% during the second quarter. Principal Financial Group Inc. now owns 95,572 shares of the biopharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 1,399 shares in the last quarter. 85.28% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/11/epizyme-epzm-trading-up-19-2.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

What are top analysts saying about Epizyme? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Epizyme and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit